Type 1 Diabetes MellitusNCT02758483
Glucose Variability in Patients With Type 1 Diabetes With a Sucrose-added Diet
A study testing Test Diet in people with Type 1 Diabetes Mellitus, run by Universidade Federal do Rio de Janeiro at 1 site in Brazil.
Trial summary
BACKGROUND: The treatment with continuous glucose monitoring system (CGMS) offers improved glycemic control for patients with type 1 diabetes. However, patients with type 1 diabetes usually intake foods with sugar, even without hypoglycemic episodes, and the use of advanced carbohydrate counting method may increase… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Type 1 Diabetes Mellitus
- What is being tested?
- Test Diet
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteBrazil
- Study dates
- 23 Mar 2017to 1 Jan 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Type 1 diabetes ( ≥ three years after diagnosis)
- Adults
- Using basal-bolus regimen with multiple insulin injections with long-acting insulin analogues (glargine, detemir, or degludec) combined with a short-acting analogs (aspart, lispro or glulisina) OR Continuous subcutaneous insulin infusion
Who cannot join
- Smokers
- Drinkers
- Use of exogenous hormone (with the exception of insulin)
- Use of antibiotics, anti-inflammatories or oral antidiabetics pharmacotherapy
- Diagnosis of nephropathy (Creatinine clearance <90mL/min/1,73m2)
- Gastroparesis symptoms
Show all 9Show fewer
- Celiac disease
- Hypothyroidism or hyperthyroidism
- Other types of diabetes family history
Trial locations and contacts
1 site in 1 country.
Brazil1 site
Clementino Fraga Filho University Hospital of Rio de Janeiro
Rio de Janeiro, 21941-913
About this study
Official title: Influence of Sucrose-free Diet or Sucrose-added Diet on Glucose Variability in Patients With Type 1 Diabetes
BACKGROUND: The treatment with continuous glucose monitoring system (CGMS) offers improved glycemic control for patients with type 1 diabetes. However, patients with type 1 diabetes usually intake foods with sugar, even without hypoglycemic episodes, and the use of advanced carbohydrate counting method may increase the calories and carbohydrate intake.
OBJECTIVE: To evaluate and compare the influence of sucrose-free diet or sucrose-added diet on glucose variability in patients with type 1 diabetes.
Read more
METHODS: The study was a simple-blind, two-way crossover design in which patients with type 1 diabetes will receive a control diet (a diet with a little quantity of sugars) or test diet (with foods containing moderate quantity of sucrose in composition) during two-days each. During the intervention, all foods and drinks intake will have to be documented to allow quantitative estimation of dietary intake, to verify adherence to the diets. After one-week, each patient will return for download CGMS.
PURPOSE: The research proposal adds knowledge about the glucose variability in patients with type 1 diabetes who use foods with sugar in theirs habitual dietary intake.
Read the detailed description
INTRODUCTION:
The continuous glucose monitoring system (CGMS) offers improved glycemic control for patients with type 1 diabetes, because may reduce asymptomatic hypoglycemic and postprandial hyperglycemia events (1, 2).
Glycemic disorder may be estimated as a whole from the determination of glycosylated hemoglobin (HbA1c) level, which integrates both hypoglycemic and hyperglycemia episodes (3). Glycemic variability is a complex phenomenon that includes both intraday and interday variability (3, 4).
The mean amplitude of glycemic excursion (MAGE) is an index for assessing the intraday glycemic variability. The calculation of the MAGE is obtained by measuring the arithmetic mean of the differences between consecutive peaks and nadirs provided that the differences are greater than one standard deviation (SD) of the mean glucose value (5).
The continuous overall net glycemic action (CONGA) index is an indicator of within-day glucose variability. After the first n number of hours of observation, the investigators may calculate the difference between current observation and observation in the previous n hours. CONGA is defined as the SD of the recorded differences. The frequently used index CONGA1, CONGA2 and CONGA4, coincide with observations lasting 1, 2, or 4 h and they are, therefore, expressions of glucose variability within these intervals (6).
The mean of daily differences (MODD) remains the sole index for estimating interday glycemic variability. This index is calculated as the mean of the absolute differences between glucose values at the same time on two consecutive days (3, 7).
Some of these indexes are complex or impossible to obtain with self-monitoring of blood glucose (SMBG). Thus, the CGMS allows to the calculation of scores (7).
Another aspect of diabetes treatment is the nutritional counseling. According to individuals with type 1 diabetes, diet adherence is one of the more difficult aspects of treatment (8, 9). However, nutrition therapy is essential in the management of diabetes, and meal-planning strategies for type 1 diabetes emphasize the relationship between prandial insulin dose selection and the anticipated amount of carbohydrates to be consumed (10, 11).
Carbohydrate counting is a meal-planning method that focuses on carbohydrates, and the American Diabetes Association recommends meal plans based on carbohydrate counting as a key strategy to achieving glycemic control (11).
There are two levels of carbohydrate counting. At the basic level, individuals must eat a consistent amount of carbohydrates at meals. It is useful to understand the effect of food and medication and to identify normal portion sizes, considering that one serving is equal to 15g of carbohydrates. The advanced level includes pattern management and understanding how to use insulin-to-carbohydrate ratios. Carbohydrate counting requires the ability to determine the amount of carbohydrates in each food, and it may promote weight gain when patients don't pay attention to their food choices (10, 12).
Our previous study has shown that patients with type 1 diabetes who began carbohydrate counting, especially the advanced method, increased their calories and carbohydrates intake (13).
Sucrose is a very attractive source of carbohydrate, and sweetness is considered one of the most powerful determinants of food consumption (14). Patients with diabetes type 1 appear to be especially prone to taste disorders (8).
Our previous study has shown that patients with type 1 diabetes's habitual intake sweets more than twice a week, despite hypoglycemia (13).
The use of CSII associated with the advanced carbohydrate counting may increase the calories and carbohydrate intake (15-18).
Previous studies have showed that the use of CSII with CGMS improve glycemic control, However, no study has evaluated the glucose variability in patients with type 1 diabetes in a diet with foods containing moderate quantity of sucrose.
The goal of this study is to evaluate and compare the influence of sucrose-free diet or sucrose-added diet on glucose variability in patients with type 1 diabetes, treated with CSII and CGMS.
EXPERIMENTAL DESIGN:
STUDY DESIGN:
This is a single-blind, two-way, crossover design in with patients with type 1 diabetes will be recruiting through poster advertisements or invited during routine medical appointment at the Clementino Fraga Filho University Hospital, Brazil by an investigator.
The sample size and selection by convenience. All participants will signed an informed consent.
Selected volunteers will be instruct to go to the hospital for anthropometric measurements, and insert the glucose sensor iPro2™ Professional CGMS system (Medtronic, Inc™). In addition, all volunteers will be receiving instructions to fill a 7-day food diary, and register their self-capillary blood glucose (four times/day).
In the same day, volunteers will receive a control diet (a diet with a little quantity of sugars) or test diet (with foods containing moderate quantity of sucrose in composition) during two-days each. These diets are composed by two menus: control diet for Tuesday and Wednesday, and test diet for Thursday and Friday.
If the volunteers consume the menus correctly during Tuesday to Friday, the diet on weekends is free. However, if a meal was consumed improperly (eg. more or less amounts, or inadequate replacements), Saturday or Sunday should be used to follow the menu not completed properly.
The researcher will contact daily in order to clarify possible doubts, and verify adherence to the diets.
After one-week, each volunteer will return for download CGMS, and in order to deliver the 7-day food diary.
INTERVENTION:
Percent energy from macronutrients was similar in both diets, and these were prescribed according to the American Diabetes Association guidelines (11).
Dietary energy content of: 50.7% and 54.6% carbohydrates; 21.5% and 21.2% protein; 27.7% and 23.42% total fat; 5.0% and 4.9% saturated fatty acids; 15.1% and 12.8% monounsaturated fatty acids; 7.3 and 5.9% polyunsaturated fatty acids; for control and test diets, respectively. Both diets were composed by 41g total dietary fiber.
Control diet has little quantity of sugars (30.4g/day, corresponding to 12.7% of total carbohydrates and 6.3% of total dietary energy intake), and test diet has foods containing moderate quantity of sucrose in composition (81.2g/day, corresponding to 30.2% of total carbohydrates and 16.5% of total dietary energy intake).
These diets are composed by two menus: control diet for Tuesday and Wednesday, and test diet for Thursday and Friday. The diet on weekends is free, if the volunteers consume the menus correctly during Tuesday to Friday. However, if a meal was consumed improperly (eg. more or less amounts, or inadequate replacements), Saturday or Sunday should be used to follow the menu not completed properly.
DIETARY ASSESSMENT:
Dietary intake will be evaluated from. All dietary records will be analyzed using a local nutritional software.
During those seven days, all foods and drinks consumed will have to be documented to allow quantitative estimation of dietary intake. Data were then entered into the DietPró 5.5i nutrition software (version 2010, Brazil) to convert the amount of food eaten into individual nutrients and the mean daily energy and nutrient intake for each patient will be calculated.
ANTHROPOMETRIC ASSESSMENT:
Body mass index (BMI) will be calculated as body weight in kilograms divided by the square of height in meters.
Waist circumference will be determined as the average of two measurements calculated to the nearest 0.1cm midway between the lower rib margin and the ilial crest after a normal expiration.
STATISTICAL:
Statistical analyses will be performed in SPSS software (version 20.0; SPSS Inc, Chicago, IL, USA). A p-value <0.05 will be consider statistically significant.
Qualitative variables were described as frequency, whereas quantitative variables will be describe as the mean ± standard deviations (SD) and 95% CI.
The Mann-Whitney test will be used for between-group comparison and the Wilcoxon test will be used to compare the effects of tests in each group. Spearman correlation and linear regression will be used to evaluate interactions.
Time course of glycemic datas will be analyzed with repeated measures analysis of variance two-way ANOVA.
The glycemic variability (MAGE, CONGA and MODD) will be calculated according to described by Kovatchev et al (3, 7).
- Conditions
- Type 1 Diabetes Mellitus
- Being tested
- Control diet, Test Diet
- Medical subject headings
- Diabetes Mellitus, Type 1
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Control dietOther
Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).
Test DietOther
Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).
| Study group | Role | What they receive |
|---|---|---|
| Test diet | Other | Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).
Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations. Receives: Other: Test Diet |
| Control diet | Other | Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).
Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations. Receives: Other: Control diet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compare the intraday and interday glucose variability effect of sucrose-free with a sucrose-free diet for patients with type 1 diabetes.
Intraday and interday glucose variability will be evaluated by the following indexes:
CONGA: continuous overall net glycemic action (mmol/L); MAGE: mean amplitude of glycemic excursion (mmol/L); MODD: mean of daily diferences (mmol/L).
Measured: Through study completion, an average of 1 year
Secondary outcomes (3)
Evaluate the intraday glycemic variability effect of foods containing different macronutrients quantity, through CONGA index.
CONGA: continuous overall net glycemic action (mmol/L
Measured: Through study completion, an average of 1 year
Compare the intraday glycemic variability effect of sucrose-free diet and sucrose-added diet, through MAGE index, in patients with type 1 diabetes
MAGE: mean amplitude of glycemic excursion (mmol/L)
Measured: Through study completion, an average of 1 year
Compare the interday glycemic variability effect of sucrose-free diet and sucrose-added diet, through MODD index, in patients with type 1 diabetes
MODD: mean of daily diferences (mmol/L
Measured: Through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 May 2016 (estimated)
- Study start23 Mar 2017
- Primary completion31 Jul 2017
- Study completion1 Jan 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Type 1 Diabetes MellitusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidade Federal do Rio de Janeiro
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Débora Lopes Souto, Universidade Federal do Rio de Janeiro
- Investigators
- Melanie Rodacki, PhD, Study chair, Universidade Federal do Rio de JaneiroLenita Zajdenverg, PhD, Study chair, Universidade Federal do Rio de Janeiro
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02758483
- Sponsor's protocol ID
- UFRJNutrology
- Status last verified
- Sep 2018
- First submitted
- 14 Apr 2016
- Last updated
- 28 Sep 2018
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The study was approved by Ethical Committee (Institutional Review Board)
Publications
Souto DL, Dantas JR, Oliveira MMDS, Rosado EL, Luiz RR, Zajdenverg L, Rodacki M. Does sucrose affect the glucose variability in patients with type 1 diabetes? a pilot crossover clinical study. Nutrition. 2018 Nov;55-56:179-184. doi: 10.1016/j.nut.2018.05.009. Epub 2018 Jun 8.
PubMed 30086487
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Influence of Sucrose-free Diet or Sucrose-added Diet on Glucose Variability in Patients With Type 1 Diabetes
- ClinicalTrials.gov ID
- NCT02758483
- Acronym / sponsor ID
- UFRJNutrology
- Conditions
- Type 1 Diabetes Mellitus
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- Universidade Federal do Rio de JaneiroUniversity, hospital or other
- Study start
- 23 Mar 2017 (actual)
- Primary completion
- 31 Jul 2017 (actual)
- Study completion
- 1 Jan 2018 (actual)
- First posted
- 2 May 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
BACKGROUND: The treatment with continuous glucose monitoring system (CGMS) offers improved glycemic control for patients with type 1 diabetes. However, patients with type 1 diabetes usually intake foods with sugar, even without hypoglycemic episodes, and the use of advanced carbohydrate counting method may increase the calories and carbohydrate intake.
OBJECTIVE: To evaluate and compare the influence of sucrose-free diet or sucrose-added diet on glucose variability in patients with type 1 diabetes.
METHODS: The study was a simple-blind, two-way crossover design in which patients with type 1 diabetes will receive a control diet (a diet with a little quantity of sugars) or test diet (with foods containing moderate quantity of sucrose in composition) during two-days each. During the intervention, all foods and drinks intake will have to be documented to allow quantitative estimation of dietary intake, to verify adherence to the diets. After one-week, each patient will return for download CGMS.
PURPOSE: The research proposal adds knowledge about the glucose variability in patients with type 1 diabetes who use foods with sugar in theirs habitual dietary intake.
Detailed description
INTRODUCTION:
The continuous glucose monitoring system (CGMS) offers improved glycemic control for patients with type 1 diabetes, because may reduce asymptomatic hypoglycemic and postprandial hyperglycemia events (1, 2).
Glycemic disorder may be estimated as a whole from the determination of glycosylated hemoglobin (HbA1c) level, which integrates both hypoglycemic and hyperglycemia episodes (3). Glycemic variability is a complex phenomenon that includes both intraday and interday variability (3, 4).
The mean amplitude of glycemic excursion (MAGE) is an index for assessing the intraday glycemic variability. The calculation of the MAGE is obtained by measuring the arithmetic mean of the differences between consecutive peaks and nadirs provided that the differences are greater than one standard deviation (SD) of the mean glucose value (5).
The continuous overall net glycemic action (CONGA) index is an indicator of within-day glucose variability. After the first n number of hours of observation, the investigators may calculate the difference between current observation and observation in the previous n hours. CONGA is defined as the SD of the recorded differences. The frequently used index CONGA1, CONGA2 and CONGA4, coincide with observations lasting 1, 2, or 4 h and they are, therefore, expressions of glucose variability within these intervals (6).
The mean of daily differences (MODD) remains the sole index for estimating interday glycemic variability. This index is calculated as the mean of the absolute differences between glucose values at the same time on two consecutive days (3, 7).
Some of these indexes are complex or impossible to obtain with self-monitoring of blood glucose (SMBG). Thus, the CGMS allows to the calculation of scores (7).
Another aspect of diabetes treatment is the nutritional counseling. According to individuals with type 1 diabetes, diet adherence is one of the more difficult aspects of treatment (8, 9). However, nutrition therapy is essential in the management of diabetes, and meal-planning strategies for type 1 diabetes emphasize the relationship between prandial insulin dose selection and the anticipated amount of carbohydrates to be consumed (10, 11).
Carbohydrate counting is a meal-planning method that focuses on carbohydrates, and the American Diabetes Association recommends meal plans based on carbohydrate counting as a key strategy to achieving glycemic control (11).
There are two levels of carbohydrate counting. At the basic level, individuals must eat a consistent amount of carbohydrates at meals. It is useful to understand the effect of food and medication and to identify normal portion sizes, considering that one serving is equal to 15g of carbohydrates. The advanced level includes pattern management and understanding how to use insulin-to-carbohydrate ratios. Carbohydrate counting requires the ability to determine the amount of carbohydrates in each food, and it may promote weight gain when patients don't pay attention to their food choices (10, 12).
Our previous study has shown that patients with type 1 diabetes who began carbohydrate counting, especially the advanced method, increased their calories and carbohydrates intake (13).
Sucrose is a very attractive source of carbohydrate, and sweetness is considered one of the most powerful determinants of food consumption (14). Patients with diabetes type 1 appear to be especially prone to taste disorders (8).
Our previous study has shown that patients with type 1 diabetes's habitual intake sweets more than twice a week, despite hypoglycemia (13).
The use of CSII associated with the advanced carbohydrate counting may increase the calories and carbohydrate intake (15-18).
Previous studies have showed that the use of CSII with CGMS improve glycemic control, However, no study has evaluated the glucose variability in patients with type 1 diabetes in a diet with foods containing moderate quantity of sucrose.
The goal of this study is to evaluate and compare the influence of sucrose-free diet or sucrose-added diet on glucose variability in patients with type 1 diabetes, treated with CSII and CGMS.
EXPERIMENTAL DESIGN:
STUDY DESIGN:
This is a single-blind, two-way, crossover design in with patients with type 1 diabetes will be recruiting through poster advertisements or invited during routine medical appointment at the Clementino Fraga Filho University Hospital, Brazil by an investigator.
The sample size and selection by convenience. All participants will signed an informed consent.
Selected volunteers will be instruct to go to the hospital for anthropometric measurements, and insert the glucose sensor iPro2™ Professional CGMS system (Medtronic, Inc™). In addition, all volunteers will be receiving instructions to fill a 7-day food diary, and register their self-capillary blood glucose (four times/day).
In the same day, volunteers will receive a control diet (a diet with a little quantity of sugars) or test diet (with foods containing moderate quantity of sucrose in composition) during two-days each. These diets are composed by two menus: control diet for Tuesday and Wednesday, and test diet for Thursday and Friday.
If the volunteers consume the menus correctly during Tuesday to Friday, the diet on weekends is free. However, if a meal was consumed improperly (eg. more or less amounts, or inadequate replacements), Saturday or Sunday should be used to follow the menu not completed properly.
The researcher will contact daily in order to clarify possible doubts, and verify adherence to the diets.
After one-week, each volunteer will return for download CGMS, and in order to deliver the 7-day food diary.
INTERVENTION:
Percent energy from macronutrients was similar in both diets, and these were prescribed according to the American Diabetes Association guidelines (11).
Dietary energy content of: 50.7% and 54.6% carbohydrates; 21.5% and 21.2% protein; 27.7% and 23.42% total fat; 5.0% and 4.9% saturated fatty acids; 15.1% and 12.8% monounsaturated fatty acids; 7.3 and 5.9% polyunsaturated fatty acids; for control and test diets, respectively. Both diets were composed by 41g total dietary fiber.
Control diet has little quantity of sugars (30.4g/day, corresponding to 12.7% of total carbohydrates and 6.3% of total dietary energy intake), and test diet has foods containing moderate quantity of sucrose in composition (81.2g/day, corresponding to 30.2% of total carbohydrates and 16.5% of total dietary energy intake).
These diets are composed by two menus: control diet for Tuesday and Wednesday, and test diet for Thursday and Friday. The diet on weekends is free, if the volunteers consume the menus correctly during Tuesday to Friday. However, if a meal was consumed improperly (eg. more or less amounts, or inadequate replacements), Saturday or Sunday should be used to follow the menu not completed properly.
DIETARY ASSESSMENT:
Dietary intake will be evaluated from. All dietary records will be analyzed using a local nutritional software.
During those seven days, all foods and drinks consumed will have to be documented to allow quantitative estimation of dietary intake. Data were then entered into the DietPró 5.5i nutrition software (version 2010, Brazil) to convert the amount of food eaten into individual nutrients and the mean daily energy and nutrient intake for each patient will be calculated.
ANTHROPOMETRIC ASSESSMENT:
Body mass index (BMI) will be calculated as body weight in kilograms divided by the square of height in meters.
Waist circumference will be determined as the average of two measurements calculated to the nearest 0.1cm midway between the lower rib margin and the ilial crest after a normal expiration.
STATISTICAL:
Statistical analyses will be performed in SPSS software (version 20.0; SPSS Inc, Chicago, IL, USA). A p-value <0.05 will be consider statistically significant.
Qualitative variables were described as frequency, whereas quantitative variables will be describe as the mean ± standard deviations (SD) and 95% CI.
The Mann-Whitney test will be used for between-group comparison and the Wilcoxon test will be used to compare the effects of tests in each group. Spearman correlation and linear regression will be used to evaluate interactions.
Time course of glycemic datas will be analyzed with repeated measures analysis of variance two-way ANOVA.
The glycemic variability (MAGE, CONGA and MODD) will be calculated according to described by Kovatchev et al (3, 7).
Study design
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Test diet | Other | Other: Test DietDiet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet). Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations. |
| Control diet | Other | Other: Control dietDiet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet). Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Type 1 diabetes ( ≥ three years after diagnosis)
- Adults
- Using basal-bolus regimen with multiple insulin injections with long-acting insulin analogues (glargine, detemir, or degludec) combined with a short-acting analogs (aspart, lispro or glulisina) OR Continuous subcutaneous insulin infusion
Key exclusion criteria (9 listed)
- Smokers
- Drinkers
- Use of exogenous hormone (with the exception of insulin)
- Use of antibiotics, anti-inflammatories or oral antidiabetics pharmacotherapy
- Diagnosis of nephropathy (Creatinine clearance <90mL/min/1,73m2)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Control dietDiet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet). | Other | Control diet |
| Test DietDiet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet). | Other | Test diet |
Primary outcome
Compare the intraday and interday glucose variability effect of sucrose-free with a sucrose-free diet for patients with type 1 diabetes.
Time frame: Through study completion, an average of 1 year
Intraday and interday glucose variability will be evaluated by the following indexes: CONGA: continuous overall net glycemic action (mmol/L); MAGE: mean amplitude of glycemic excursion (mmol/L); MODD: mean of daily diferences (mmol/L).
3 secondary outcomes
Evaluate the intraday glycemic variability effect of foods containing different macronutrients quantity, through CONGA index.
Time frame: Through study completion, an average of 1 year
Compare the intraday glycemic variability effect of sucrose-free diet and sucrose-added diet, through MAGE index, in patients with type 1 diabetes
Time frame: Through study completion, an average of 1 year
Compare the interday glycemic variability effect of sucrose-free diet and sucrose-added diet, through MODD index, in patients with type 1 diabetes
Time frame: Through study completion, an average of 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2018.
- Results publication: PubMed 30086487Souto DL, Dantas JR, Oliveira MMDS, Rosado EL, Luiz RR, Zajdenverg L, Rodacki M. Does sucrose affect the glucose variability in patients with type 1 diabetes? a pilot crossover clinical study. Nutrition. 2018 Nov;55-56:179-184. doi: 10.1016/j.nut.2018.05.009. Epub 2018 Jun 8.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided. The study was approved by Ethical Committee (Institutional Review Board)
Related trials for Type 1 Diabetes Mellitus
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
RecruitingPhase 1
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Melanoma
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Melanie Rodacki, PhD study chair
Universidade Federal do Rio de Janeiro
Lenita Zajdenverg, PhD study chair
Universidade Federal do Rio de Janeiro
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Test Diet in people with Type 1 Diabetes Mellitus, run by Universidade Federal do Rio de Janeiro at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Sep 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compare the intraday and interday glucose variability effect of sucrose-free with a sucrose-free diet for patients with type 1 diabetes. (time frame: Through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02758483, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2018.